查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1435150

抗驚厥藥物市場：依藥物類型、適應症分類 - 2024-2030 年全球預測

Anticonvulsants Market by Drug types (AMPA, Barbiturate, Benzodiazepine), Indication (Anxiety, Bipolar Disorder, Borderline Personality Disorder) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗驚厥藥物市場規模為120.3億美元，預計2024年將達130.7億美元，2030年將達215.9億美元，複合年成長率為8.71%。

全球抗驚厥藥物市場

主要市場統計
基準年[2023] 120.3億美元
預測年份 [2024] 130.7億美元
預測年份 [2030] 215.9億美元
複合年成長率（%） 8.71%
抗驚厥藥市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估抗驚厥藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗驚厥藥市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-抗驚厥藥物市場規模及預測是多少？

2-抗驚厥藥市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-抗驚厥藥物市場的技術趨勢和法律規範是什麼？

4-抗驚厥藥物市場主要供應商的市場佔有率是多少？

5-進入抗驚厥藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 年輕人和老年人的癲癇盛行率增加
      • 政府加大力度支持癲癇意識
      • 擴大在非癲癇疾病治療的應用
    • 抑制因素
      • 疼痛管理替代方案的可用性
    • 機會
      • 抗驚厥藥物的監管核准增加
      • 新一代抗癲癇藥物的出現
    • 任務
      • 供不應求及二代藥專利到期
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章依藥物類型分類的抗驚厥藥物市場

  • 安帕
  • 巴比妥類
  • 苯二氮平類
  • 氨基甲酸酯類抗驚厥藥
  • 碳酸酐酶抑制劑
  • 二苯並氮卓
  • 三嗪

第7章 抗驚厥藥物市場適應症

  • 焦慮
  • 躁鬱症
  • 邊緣性人格障礙
  • 癲癇
  • 纖維肌痛
  • 偏頭痛
  • 神經性疼痛

第8章美洲抗驚厥藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區抗驚厥藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲抗驚厥藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析

第12章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • Astrazeneca PLC
    • Bausch Health Companies Inc.
    • Biocon Limited
    • Cadila Pharmaceuticals Limited
    • Cipla, Inc.
    • Dr. Reddy's Laboratories Limited
    • Eisai Co., Ltd.
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Ltd.
    • Jazz Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc.
    • Lifecare Neuro Products Limited
    • Lundbeck A/S
    • Mankind Pharma Ltd.
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk A/S
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Sanofi SA
    • Sunovion Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Wockhardt Limited
  • 主要產品系列

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-ED54C46E805C

[192 Pages Report] The Anticonvulsants Market size was estimated at USD 12.03 billion in 2023 and expected to reach USD 13.07 billion in 2024, at a CAGR 8.71% to reach USD 21.59 billion by 2030.

Global Anticonvulsants Market

KEY MARKET STATISTICS
Base Year [2023] USD 12.03 billion
Estimated Year [2024] USD 13.07 billion
Forecast Year [2030] USD 21.59 billion
CAGR (%) 8.71%
Anticonvulsants Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anticonvulsants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anticonvulsants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anticonvulsants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Dr. Reddy's Laboratories Limited, Eisai Co., Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Lifecare Neuro Products Limited, Lundbeck A/S, Mankind Pharma Ltd., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Anticonvulsants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug types
    • AMPA
    • Barbiturate
    • Benzodiazepine
    • Carbamate Anticonvulsants
    • Carbonic Anhydrase Inhibitor
    • Dibenzazepine
    • Triazine
  • Indication
    • Anxiety
    • Bipolar Disorder
    • Borderline Personality Disorder
    • Epilepsy
    • Fibromyalgia
    • Migraine
    • Neuropathic Pain
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anticonvulsants Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anticonvulsants Market?

3. What are the technology trends and regulatory frameworks in the Anticonvulsants Market?

4. What is the market share of the leading vendors in the Anticonvulsants Market?

5. Which modes and strategic moves are suitable for entering the Anticonvulsants Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anticonvulsants Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of epilepsy among young and senior population
      • 5.1.1.2. Rising government initiatives supporting epilepsy awareness
      • 5.1.1.3. Expanding use in treating nonepileptic conditions
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of substitutes options for pain management
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
      • 5.1.3.2. Emergence of new-generation antiepileptic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Drug supply shortage and patent expiration of the second-generation drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anticonvulsants Market, by Drug types

  • 6.1. Introduction
  • 6.2. AMPA
  • 6.3. Barbiturate
  • 6.4. Benzodiazepine
  • 6.5. Carbamate Anticonvulsants
  • 6.6. Carbonic Anhydrase Inhibitor
  • 6.7. Dibenzazepine
  • 6.8. Triazine

7. Anticonvulsants Market, by Indication

  • 7.1. Introduction
  • 7.2. Anxiety
  • 7.3. Bipolar Disorder
  • 7.4. Borderline Personality Disorder
  • 7.5. Epilepsy
  • 7.6. Fibromyalgia
  • 7.7. Migraine
  • 7.8. Neuropathic Pain

8. Americas Anticonvulsants Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anticonvulsants Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anticonvulsants Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. Astrazeneca PLC
    • 12.1.3. Bausch Health Companies Inc.
    • 12.1.4. Biocon Limited
    • 12.1.5. Cadila Pharmaceuticals Limited
    • 12.1.6. Cipla, Inc.
    • 12.1.7. Dr. Reddy's Laboratories Limited
    • 12.1.8. Eisai Co., Ltd.
    • 12.1.9. GlaxoSmithKline PLC
    • 12.1.10. Glenmark Pharmaceuticals Ltd.
    • 12.1.11. Jazz Pharmaceuticals, Inc.
    • 12.1.12. Johnson & Johnson Services, Inc.
    • 12.1.13. Lifecare Neuro Products Limited
    • 12.1.14. Lundbeck A/S
    • 12.1.15. Mankind Pharma Ltd.
    • 12.1.16. Merck KGaA
    • 12.1.17. Novartis AG
    • 12.1.18. Novo Nordisk A/S
    • 12.1.19. Otsuka Pharmaceutical Co., Ltd.
    • 12.1.20. Pfizer Inc.
    • 12.1.21. Sanofi S.A.
    • 12.1.22. Sunovion Pharmaceuticals Inc.
    • 12.1.23. Takeda Pharmaceutical Company Limited
    • 12.1.24. Teva Pharmaceutical Industries Ltd.
    • 12.1.25. Wockhardt Limited
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTICONVULSANTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICONVULSANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTICONVULSANTS MARKET DYNAMICS
  • FIGURE 7. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2030 (%)
  • FIGURE 8. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICONVULSANTS MARKET SIZE, BY AMPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 108. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 109. ANTICONVULSANTS MARKET LICENSE & PRICING